Autres langues PCL, Inc.

Actions

A241820

KR7241820000

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 18/04/2024			Varia. 5j.	Varia. 1 janv.
1 247 ^KRW	+0,16 %		+1,05 %	-65,22 %

2023	Les actions sud-coréennes clôturent en baisse alors que les incertitudes concernant l'accord sur le plafond de la dette américaine demeurent ; PCL perd 13%.	MT
2023	PCL, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2022	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	16/01
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	26/12
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	21/12
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets	15/12
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	31/05/23
PCL to Raise 36 Billion Won via Share Issuance	31/05/23
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	29/12/22
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4%	22/12/22
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	21/12/22
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.	12/12/22
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding	12/12/22
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.	11/11/22
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.	11/11/22
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index	07/04/22
PCL, Inc.(KOSDAQ:A241820) added to S&P Global BMI Index	20/09/21
MCureX Therapeutics, Inc. announced that it expects to receive KRW 2 billion in funding from OliX Pharmaceuticals,Inc, PCL, Inc., Samyang Holdings Corporation	23/06/21
PCL, Inc. announced that it has received KRW 40.499938368 billion in funding from a group of investors	25/03/21
Datametrex AI Limited Secures Authorization by Health Canada for PCL Inc.'s COVID19 Rapid Antigen Test Kit	23/03/21
PCL, Inc. announced that it expects to receive KRW 40.499938368 billion in funding from a group of investors	18/03/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PCL, Inc.

Actions

A241820

KR7241820000

Autres langues

Filtres